title: Original version Date: 4/12/2018
text: |
  Original version Date: 4/12/2018
  |
  bet | 509/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Original version Date: 4/12/2018
  |
  Author: NMF Consensus Group
  |
  Current Version number: 1
  |
  Current Version Date: 13/12/2018
  |
  Risk Rating: Low
  |
  Due for Review: 13/12/2023
  |
  Approval by: DTC
  |
  Approval Date:
  |
  Propranolol |
  Revision Date : 15-4-2019
  |
  Approved: TC, KOH
  |
  Alert
  |
  For dosing on infantile haemangiomas – please refer to “Propranolol for Infantile Haemangioma” formulary.
  For infants with comorbidities that are likely to lead to hypoglycaemia (e.g.
  hyperinsulinism/preterm/low weight) – dose schedule needs to be cautious.
  Ensure infant has adequate enteral or parenteral nutrient intake.
  |
  Indication
  |
  Supraventricular and ventricular tachycardia
  Prevention of hypercyanotic episodes in unrepaired Tetralogy of Fallot
  Hypertrophic cardiomyopathy
  Systemic hypertension
  Thyrotoxicosis – treatment of sympathetic overactivity
  Phaeochromocytoma (with an alpha-blocker)
  Retinopathy of prematurity (not recommended)
  Infantile haemangioma – Please refer to “Propranolol for Infantile Haemangioma”
  formulary.
  |
  Action
  |
  Beta-blockers competitively block beta-adrenoceptors in heart, peripheral vasculature, bronchi, pancreas, uterus, kidney, brain and liver. Beta-blockers reduce heart rate, blood pressure (BP) and cardiac contractility; also depress sinus node rate and slow conduction through the atrioventricular (AV) node and prolong atrial refractory periods.
  |
  Drug Type
  |
  Beta-adrenergic blocker
  |
  Trade Name
  |
  Deralin, Inderal tablets, Hemangiol, Propranolol Auspman
  |
  Presentation
  |
  Deralin, Inderal, tablet 10 mg, 40 mg,
  Deralin tablet 160 mg
  Propranolol (Auspman) 2 mg/mL Oral Solution
  Hemangiol 3.75 mg/mL Oral Solution
  Propranolol suspension (formulas for multiple concentrations exist) compounded by
  Pharmacy Department
  |
  |
  |
  | |